Overview

Hydrocortisone for COVID-19 and Severe Hypoxia

Status:
Completed
Trial end date:
2021-09-08
Target enrollment:
Participant gender:
Summary
We aim to assess the benefits and harms of low-dose hydrocortisone in patients with COVID-19 and severe hypoxia.
Phase:
Phase 3
Details
Lead Sponsor:
Scandinavian Critical Care Trials Group
Collaborators:
Aarhus University Hospital
Copenhagen Trial Unit, Center for Clinical Intervention Research
Rigshospitalet, Denmark
University of Copenhagen
Treatments:
Hydrocortisone
Hydrocortisone hemisuccinate